Home › Funds › FLOSSBACH VON STORCH SE › BNTX
FLOSSBACH VON STORCH SE position in BNTX
BIONTECH SE · Health Care
FLOSSBACH VON STORCH SE reported holding 2,226,138 shares of BNTX (BIONTECH SE) in its Q2 2026 13F filing — a position valued at US$207.1M, representing 0.94% of its reported portfolio and ranking #32 among its reported holdings. FLOSSBACH VON STORCH SE has disclosed BNTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How FLOSSBACH VON STORCH SE's BNTX position evolved
FLOSSBACH VON STORCH SE first disclosed a stake in BNTX in Q3 2023 at 3,513,215 shares (US$381.7M). The position peaked in Q3 2024 at 4,359,607 shares, worth US$517.8M. Across 12 filings, FLOSSBACH VON STORCH SE increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,226,138 shares valued at US$207.1M — a reduction of -1,454,177 shares quarter over quarter.. Notable position changes include a 26% increase in Q2 2024 (shares rose 48% over the following quarter), a 40% trim in Q2 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.51M | $381.68M | New |
| Q4 2023 | 3.55M | $374.53M | Add |
| Q1 2024 | 3.47M | $320.01M | Reduce |
| Q2 2024 | 4.38M | $351.94M | Add |
| Q3 2024 | 4.36M | $517.79M | Hold |
| Q4 2024 | 4.41M | $502.16M | Add |
| Q1 2025 | 4.26M | $387.88M | Reduce |
| Q2 2025 | 4.23M | $450.38M | Reduce |
| Q3 2025 | 4.23M | $417.17M | Hold |
| Q4 2025 | 4.20M | $399.46M | Reduce |
| Q1 2026 | 3.68M | $327.11M | Reduce |
| Q2 2026 | 2.23M | $207.14M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BNTX and 13F data
BNTX (BIONTECH SE) is a Health Care company. 34 other funds we track also report a position in BNTX — the largest reported positions include Temasek Holdings (Private) Ltd (US$140.1M), Logos Global Management LP (US$94.4M), GSK plc (US$82.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BNTX
- Temasek Holdings (Private) Ltd 1.51M sh · $140.14M · Q2 2026
- Logos Global Management LP 1.01M sh · $94.45M · Q2 2026
- GSK plc 889.82K sh · $82.80M · Q2 2026
- Davern Capital Partners, LP 754.55K sh · $70.21M · Q2 2026
- Long Focus Capital Management, LLC 624.00K sh · $58.06M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 470.00K sh · $43.73M · Q2 2026
More on FLOSSBACH VON STORCH SE
FAQ
How long has FLOSSBACH VON STORCH SE held BNTX?
FLOSSBACH VON STORCH SE has disclosed BNTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is FLOSSBACH VON STORCH SE's current position in BNTX?
As of Q2 2026, FLOSSBACH VON STORCH SE holds 2.23M shares of BNTX (BIONTECH SE), valued at $207.14M, representing 0.94% of its reported portfolio and ranking #32.
Has FLOSSBACH VON STORCH SE been buying or selling BNTX?
In the latest 13F filing (Q2 2026), FLOSSBACH VON STORCH SE reduced its position in BNTX. The position peaked in Q3 2024 at 4.36M shares.
Which other funds hold BNTX?
Other major institutional holders of BNTX include Temasek Holdings (Private) Ltd, Logos Global Management LP, GSK plc, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.